(Q37024414)

17 August 2017

1 reference

title

Rosiglitazone and cardiovascular risk: weighing recent evidence (English)

1 reference

17 August 2017

1 reference

Panagiotis C Stafylas

series ordinal

1

1 reference

17 August 2017

Pantelis A Sarafidis

series ordinal

2

1 reference

17 August 2017

Anastasios N Lasaridis

series ordinal

3

1 reference

17 August 2017

publication date

1 January 2007

1 reference

Journal of the cardiometabolic syndrome

17 August 2017

published in

1 reference

17 August 2017

volume

2

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

295-296

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07744.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07744.X

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07744.X

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07744.X

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07744.X

10.1111/J.1559-4564.2007.07744.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference